OFT: Boot and Alliance will not go before the Competition Commission

13 February 2006

l The boards of UK pharmacy and general retailer The Boots Group and Alliance Unichem, a UK-headquartered European drug distributor, say that the UK Office of Fair Trading has decided not to refer their merger, which was proposed last year (Marketletter October 10, 2005), for review by the Competition Commission under the provisions of the Enterprise Act 2002. The two companies say they will work together to address the OFT's concerns relating to the prospect of a substantial lessening of competition in around 100 local areas identified by the OFT. The combination of the two companies would create Europe's leading retail pharmacy business comprising just under 3,000 retail outlets and a combined turnover of $23.11 billion, with a wholesaler and distribution network serving over 88,000 outlets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight